Form D · Biotechnology

20/20 GeneSystems, Inc.

Gaithersburg, MD · CIK 0001139685

Offering snapshot reported Feb 26, 2025 · SEC filing

Reported sold
$70K
Offering amount: $3M
Investors reported
3
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 21, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 26, 2025Initial$70,000No comparison3SEC filing
Feb 19, 2016Amendment$2,513,413$355,000vs Oct 30, 201566SEC filing
Feb 4, 2016Initial$2,000,000No comparison1SEC filing
Oct 30, 2015Amendment$2,158,413$121,399vs Sep 22, 201549SEC filing
Sep 22, 2015Initial$2,037,014No comparison45SEC filing

Offering details

Securities
Debt, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-539305

Source: Form D, filed Feb 26, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jonathan Cohen Director, Executive
Richard M. Cohen Director
John G Compton Director
Dean Hautamaki Director
Michael Hertzberg Director
Joel Kanter Director, Executive
Vladimir Knezevic Director
Wei Lu Director
Caroline Popper Director
Prasanth Reddy Director
John W. Rollins Director
Michael A Ross Director
Anne Shiflett Executive
Larry Shulman Director
Donald Wallach Director
Jiminy Zhou Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
15810 Gaither Road, Suite 235
Gaithersburg, MD, 20877